Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, CRISPR Therapeutics AG (CRSP) has a Wall Street consensus price target of $65.00, based on estimates from 38 covering analysts. With the stock currently trading at $60.14, this represents a potential upside of +8.1%. The company has a market capitalization of $5.65B.
Analyst price targets range from a low of $33.00 to a high of $82.00, representing a 75% spread in expectations. The median target of $74.50 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 22 analysts rating the stock as a Buy or Strong Buy,14 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, CRSP trades at a trailing P/E of -9.3x. Analysts expect EPS to grow +9.7% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CRSP stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for CRSP is $65, close to the current price of $60.14 (8.1% implied move). Based on 38 analyst estimates, the stock appears fairly valued near current levels.
CRSP has a consensus rating of "Buy" based on 38 Wall Street analysts. The rating breakdown is predominantly bullish, with 22 Buy/Strong Buy ratings. The consensus 12-month price target of $65 implies 8.1% upside from current levels.
CRSP's current price is $60.14 with a consensus target of $65 (8.1% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $82 for CRSP, while the most conservative target is $33. The consensus of $65 represents the median expectation. These targets typically reflect 12-month expectations.
CRSP is heavily covered by Wall Street, with 38 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 22 have Buy ratings, 14 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CRSP stock forecast based on 38 Wall Street analysts shows a consensus price target of $65, with estimates ranging from $33 (bear case) to $82 (bull case). The median consensus rating is "Buy".
CRSP appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $65 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CRSP analyst price targets range from $33 to $82, a 75% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $65 consensus represents the middle ground.